🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 87 of 116

  1. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  2. A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors

    Revolution Medicines

    Participants with Advanced KRASG12C-Mutated Solid Tumors

    phase 1 other active

    1 trial

  3. A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations, Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

    phase 1 other active

    1 trial

  4. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  5. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  6. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  7. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  8. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  9. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  10. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  11. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  12. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  13. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  14. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

  15. A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors

    AstraZeneca AB

    Advanced solid tumour

    phase 1 other active

    1 trial

  16. A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  17. A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  18. A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  19. A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  20. A-CAR028

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  21. AB308

    Arcus Biosciences

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  22. AB598

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  23. AB680

    Arcus Biosciences

    Advanced Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  24. AB801

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  25. AB801

    Arcus Biosciences

    Cancer

    phase 1 small molecule completed

    1 trial

  26. ACR-2316

    Acrivon Therapeutics

    Specific Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  27. ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

    Actinium Pharmaceuticals

    Leukemia

    phase 1 mab completed

    1 trial

  28. ACTR T Cell Product

    Cogent Biosciences

    Solid Tumor

    phase 1 mab terminated

    1 trial

  29. ACTR087

    Cogent Biosciences

    Lymphoma

    phase 1 mab completed

    1 trial

  30. ACTR707

    Cogent Biosciences

    Lymphoma

    phase 1 mab terminated

    1 trial

  31. ADCLEC.syn1 CAR T cells

    Takeda

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  32. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  33. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  34. ADCT-402

    ADC Therapeutics SA

    Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  35. ADCT-402

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  36. ADCT-502

    ADC Therapeutics SA

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  37. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials

  38. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  39. ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.

    Pfizer Australia Pty Ltd

    metastatic/advanced breast cancer

    phase 1 other active

    1 trial

  40. AG-636

    Agios Netherlands B.V.

    Lymphoma

    phase 1 small molecule terminated

    1 trial

  41. AG881

    Agios Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule completed

    1 trial

  42. ALLO-316

    Allogene Therapeutics

    Advanced/Metastatic Clear Cell Renal Cell Carcinoma

    phase 1 gene therapy active

    1 trial

  43. ALLO-501

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 1 gene therapy completed

    1 trial

  44. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  45. ALN-VSP02

    Alnylam Netherlands B.V.

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  46. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  47. AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  48. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.